Research programme: antibody therapeutics - Champions Oncology

Drug Profile

Research programme: antibody therapeutics - Champions Oncology

Alternative Names: TAR-1

Latest Information Update: 08 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tel Aviv University
  • Developer Champions Oncology
  • Class Antibodies
  • Mechanism of Action Tumour suppressor protein p53 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 04 Apr 2011 Champions Biotechnology is now called Champions Oncology
  • 01 Apr 2011 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 03 Nov 2010 Champions Biotechnology receives Qualifying Therapeutics Discovery Project grant from the US Department of Health and Human Services for antibody therapeutics development in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top